U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07180511) titled 'A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.' on Sept. 10.
Brief Summary: To evaluate the efficacy of QY201 tablets in the treatment of adult patients with moderate to severe atopic dermatitis (AD).
Study Start Date: March 12
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis (AD)
Intervention:
DRUG: 10mg QY201 Placebo tablet
10mg QY201 Placebo tablet
DRUG: 20mg QY201 Placebo tablet
20mg QY201 Placebo tablet
DRUG: 10mg QY201 tablet
10mg QY201 tablet
DRUG: 20mg QY201 tablet
20mg QY201 tablet
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: E-nitiate Biophar...